In patients with Barrett’s esophagus (BE), acid suppression with proton pump inhibitors (PPIs) and histamine, -receptor antagonists (H2RA) reduced the risk of progression to esophageal adenocarcinoma (EAC), according to findings presented at the annual Digestive Disease Week
http://www.philstar.com/opinion/2016/12/11/1652302/acid-suppression-cuts-cancer-risk-barretts-esophagus
Acid suppression cuts cancer risk in Barrett’s esophagus